Dr. Young on Other Options for Managing Bleeding in Children With Cancer

Guy Young, MD
Published: Monday, Oct 23, 2017



Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 


Guy Young, MD, director, Hemostasis and Thrombosis Program, attending physician, Hematology, Oncology and Blood and Marrow Transplantation, Children’s Hospital Los Angeles, USC, discusses other options for managing bleeding in children with cancer.

For hospitalized children with cancer who develop a blood clot, bivalirudin (Angiomax), an intravenous-direct thrombin inhibitor, can be better than the traditionally-used heparin therapy, says Young.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Publication Bottom Border
Border Publication
x